1. Volume 2, Issue 1, Pages e12-e19 (January 2015)
Partner-based adherence intervention for second-line antiretroviral therapy (ACTG A5234): a multinational randomised trial 
Dr Robert Gross, MD, Lu Zheng, PhD, Alberto La Rosa, MD, Xin Sun, MS, Susan L Rosenkranz, PhD, Sandra Wagner Cardoso, MD, Francis Ssali, MBBCh, Rob Camp, Catherine Godfrey, MD, Prof Susan E Cohn, MD, Gregory K Robbins, MD, Anthony Chisada, MD, Carole L Wallis, PhD, Prof Nancy R Reynolds, PhD, Darlene Lu, MS, Prof Steven A Safren, PhD, Lara Hosey, MA, Patrice Severe, MD, Prof Ann C Collier, MD 
The Lancet HIV 
Volume 2, Issue 1, Pages e12-e19 (January 2015)
DOI: /S (14)
Copyright © 2015 Elsevier Ltd Terms and Conditions

2. Figure 1
Trial profile
*Antiretroviral therapy included lopinavir/ritonavir and emtricitabine/tenofovir disoproxil fumarate.
The Lancet HIV 2015 2, e12-e19DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

3. Figure 2
Proportion of participants with HIV RNA concentrations of 400 copies per mL or less
Error bars show 95% CIs. We categorised missing data as treatment failure. SOC=standard of care. mDOT=modified directly observed therapy.
The Lancet HIV 2015 2, e12-e19DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions

4. Figure 3
Distribution of adherence categories by group per yearly quarter
Shading is darker for lower adherence and lighter for higher adherence. mDOT=modified directly observed therapy. SOC=standard of care.
The Lancet HIV 2015 2, e12-e19DOI: ( /S (14) )
Copyright © 2015 Elsevier Ltd Terms and Conditions